Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds

Xu,Jiasheng; Min,Dinghong; Guo,Guanghua; Liao,Xincheng; Fu,Zhonghua

doi:10.3892/etm.2018.6131

Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds

Authors:
- Jiasheng Xu
- Dinghong Min
- Guanghua Guo
- Xincheng Liao
- Zhonghua Fu
View Affiliations

Affiliations: Burn Center, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330001, P.R. China
Published online on: May 3, 2018 https://doi.org/10.3892/etm.2018.6131
Pages: 5365-5370

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of epidermal growth factor (EGF) and acidic fibroblast growth factor (aFGF) on the healing of diabetic foot wounds. A total of 199 patients with diabetic foot ulcers were recruited and randomly divided into four groups: A recombinant human EGF group (n=50), an aFGF group (n=50), a combined EGF and aFGF group (n=50) and a normal saline control group (n=49). Patients in all groups received a daily dressing change and growth factor reagents were applied topically when dressing. To observe the time required for each stage of wound healing, the epidermal healing rate and granulation tissue growth were recorded. Following 3‑4 days of treatment, the wound healing stage was similar in all groups. Later stages (following 4 days) of wound healing were achieved significantly faster in the combined group compared with the control group (P<0.05). The rate of wound healing in the EGF group was similar to that observed in the combination group. No significant difference was observed between the EGF and aFGF groups during the initial period of wound healing. However, in the later stage (following 4 days), the combined use of recombinant human EGF and aFGF had a marked positive effect on wound healing when compared with the control group. Growth factors have extensive biological activities with functions including promoting cell proliferation as well as rehabilitating and regenerating tissues, which serve important roles in wound healing.

View Figures

View References

1	Everett E and Mathioudakis N: Update on management of diabetic foot ulcers. Ann NY Acad Sci. 1411:153–165. 2018. View Article : Google Scholar : PubMed/NCBI
2	Babaei V, Afradi H, Gohardani HZ, Nasseri F, Azarafza M and Teimourian S: Management of chronic diabetic foot ulcers using platelet-rich plasma. J Wound Care. 26:784–787. 2017. View Article : Google Scholar : PubMed/NCBI
3	Dinh T, Tecilazich F, Kafanas A, Doupis J, Gnardellis C, Leal E, Tellechea A, Pradhan L, Lyons TE, Giurini JM and Veves A: Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 61:2937–2947. 2012. View Article : Google Scholar : PubMed/NCBI
4	Demidova-Rice TN, Hamblin MR and Herman IM: Acute and impaired wound healing: Pathophysiology and current methods for drug delivery, part 2: Role of growth factors in normal and pathological wound healing: Therapeutic potential and methods of delivery. Adv Skin Wound Care. 25:349–370. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sridharan K and Sivaramakrishnan G: Growth factors for diabetic foot ulcers: Mixed treatment comparison analysis of randomized clinical trials. Br J Clin Pharmacol. 84:434–444. 2017. View Article : Google Scholar
6	Laiva AL, O'Brien FJ and Keogh MB: Innovations in gene and growth factor delivery systems for diabetic wound healing. J Tissue Eng Regen Med. May 8–2017.(Epub ahead of print). PubMed/NCBI
7	Stern MP, Valdez RA, Haffner SM, Mitchell BD and Hazuda HP: Stability over time of modern diagnostic criteria for type II diabetes. Diabetes Care. 16:978–983. 1993. View Article : Google Scholar : PubMed/NCBI
8	Wagner FW: Transcutaneous Doppler ultrasound in the prediction of healing and the selection of surgical level for dysvascular lesions of the toes and forefoot. Clin Orthop Relat Res. 142:110–114. 1979.
9	Al-Rubeaan K, Al Derwish M, Ouizi S, Youssef AM, Subhani SN, Ibrahim HM and Alamri BN: Diabetic foot complications and their risk factors from a large retrospective cohort study. PLoS One. 10:e01244462015. View Article : Google Scholar : PubMed/NCBI
10	Naz I, Walters E, Akbari CM, Attinger CE and Kim PJ: Noninvasive vascular assessment of lower extremity wounds in diabetics: Are we able to predict perfusion deficits? Surg Technol Int. 31:66–74. 2017.PubMed/NCBI
11	Gope ML and Gope R: Tyrosine phosphorylation of EGF-R and PDGF-R proteins during acute cutaneous wound healing process in mice. Wound Repair Regen. 17:71–79. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pastore S, Mascia F, Mariani V and Girolomoni G: The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol. 128:1365–1374. 2008. View Article : Google Scholar : PubMed/NCBI
13	Schumacher B, Pecher P, Von Specht BU and Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation. 97:645–650. 1998. View Article : Google Scholar : PubMed/NCBI
14	Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, et al: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation. 105:788–793. 2012. View Article : Google Scholar
15	Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, Mccluskey ER and Zioncheck TF: A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 72:20–32. 2013. View Article : Google Scholar
16	Richardson TP, Peters MC, Ennett AB and Mooney DJ: Polymeric system for dual growth factor delivery. Nat Biotechnol. 19:1029–1034. 2001. View Article : Google Scholar : PubMed/NCBI
17	Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE and Mooney DJ: Integrated approach to designing growth factor delivery systems. FASEB J. 21:3896–3903. 2007. View Article : Google Scholar : PubMed/NCBI
18	Marui A, Kanematsu A, Yamahara K, Doi K, Kushibiki T, Yamamoto M, Itoh H, Ikeda T, Tabata Y and Komeda M: Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J Vasc Surg. 41:82–90. 2015. View Article : Google Scholar
19	Ghiasi Z, Gray T, Tran P, Dubielzig R, Murphy C, McCartney DL and Reid TW: The effect of topical Substance-P plus insulin-like growth factor-1 (IGF-1) on epithelial healing after photorefractive keratectomy in rabbits. Transl Vis Sci Technol. 7:122018. View Article : Google Scholar : PubMed/NCBI
20	An Y, Liu WJ, Xue P, Ma Y, Zhang LQ, Zhu B, Qi M, Li LY, Zhang YJ, Wang QT and Jin Y: Autophagy promotes MSC-mediated vascularization in cutaneous wound healing via regulation of VEGF secretion. Cell Death Dis. 9:582018. View Article : Google Scholar : PubMed/NCBI
21	Saijo H, Kilpadi DV and Akita S: Evaluation of the use of recombinant human basic fibroblast growth factor in combination with negative pressure wound therapy with instillation and dwell time in porcine full-thickness wound model. Wound Repair Regen. Jan 12–2018.(Epub ahead of print).
22	Simmons CA, Alsberg E, Hsiong S, Kim WJ and Mooney DJ: Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone. 35:562–569. 2004. View Article : Google Scholar : PubMed/NCBI
23	Basmanav FB, Kose GT and Hasirci V: Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Biomaterials. 29:4195–4204. 2008. View Article : Google Scholar : PubMed/NCBI
24	Patel ZS, Young S, Tabata Y, Jansen JA, Wong ME and Mikos AG: Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone. 43:931–940. 2008. View Article : Google Scholar : PubMed/NCBI
25	Hutchings H, Ortega N and Plouet J: Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J. 17:1520–1522. 2013. View Article : Google Scholar
26	Tsou R and Isik FF: Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol Cell Biochem. 224:81–89. 2011. View Article : Google Scholar
27	Li B, Davidson JM and Guelcher SA: The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials. 30:3486–3494. 2009. View Article : Google Scholar : PubMed/NCBI
28	Silva AK, Richard C, Bessodes M, Scherman D and Merten OW: Growth factor delivery approaches in hydrogels. Biomacromolecules. 10:9–18. 2009. View Article : Google Scholar : PubMed/NCBI
29	Sakiyama-Elbert SE and Hubbell JA: Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 65:389–402. 2000. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Ding X, Lin X, Yang P and Lin K: Clinical observation of recombinant human epidermal growth factor combined with lipoic acid in the treatment of diabetic foot. Chin Pharm. 27:4147–4149. 2016.(In Chinese).
31	Johnson NR and Wang Y: Controlled delivery of heparin-binding EGF-like growth factor yields fast and comprehensive wound healing. J Control Release. 166:124–129. 2013. View Article : Google Scholar : PubMed/NCBI
32	Bae IH, Park JW and Kim DY: Enhanced regenerative healing efficacy of a highly skin-permeable growth factor nanocomplex in a full-thickness excisional mouse wound model. Int J Nanomedicine. 9:4551–4567. 2014.PubMed/NCBI
33	Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD and Mekkes JR: Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol. 81:153–160. 2002. View Article : Google Scholar : PubMed/NCBI
34	Nie K, Li P, Zeng X, Sun G, Jin W, Wei Z, Wang B, Qi J, Wang Y and Wang D: Clinical observation of basic fibroblast growth factor combined with topical oxygen therapy in enhancing burn wound healing. Chin J Rep Rec Surg. 6:643–646. 2010.(In Chinese).
35	Tiaka EK, Papanas N, Manolakis AC and Maltezos E: The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burns Trauma. 1:68–76. 2011.PubMed/NCBI
36	Sheridan MH, Shea LD, Peters MC and Mooney DJ: Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release. 64:91–102. 2000. View Article : Google Scholar : PubMed/NCBI
37	Chen RR and Mooney DJ: Polymeric growth factor delivery strategies for tissue engineering. Pharm Res. 20:1103–1112. 2003. View Article : Google Scholar : PubMed/NCBI
38	Zhu XH, Wang CH and Tong YW: In vitro characterization of hepatocyte growth factor release from PHBV/PLGA microsphere scaffold. J Biomed Mater Res A. 89:411–423. 2009. View Article : Google Scholar : PubMed/NCBI
39	Pepper MS, Ferrara N, Orci L and Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 189:824–831. 1992. View Article : Google Scholar : PubMed/NCBI
40	Hamann Jimenez MC, Tator CH and Shoichet MS: Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp Neurol. 194:106–119. 2005. View Article : Google Scholar : PubMed/NCBI
41	Yang HS, Shin J, Bhang SH, Shin JY, Park J, Im GI, Kim CS and Kim BS: Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma. Exp Mol Med. 43:622–629. 2011. View Article : Google Scholar : PubMed/NCBI